drugset / Trial / NCT04248153

Optimal Timing of BR55 CEUS of the Ovaries

NCT04248153 ↗

RandomizedParallel-groupOpen-labelDiagnostic

Summary

This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.

Timeline

Start
2019-10-14
Primary completion
2020-02-19
Completion
2021-07-31

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor decision; expiration of available study agent due to long recruitment timeline.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BR55 Diagnostic / imaging agent 0.03 ml —
Subject BR55 Diagnostic / imaging agent 0.05 ml —

Indications